Global assays in hemophilia

Seminars in Hematology

Volumn 53, Issue 1, 2016, Pages 40-45

  Chitlur, Meera ^a   Young, Guy ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Global assays; Hemophilia; Hemostasis; Thrombin generation; Thromboelastography

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

BLEEDING; BLOOD CLOTTING TEST; HEMOPHILIA; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REVIEW; STANDARDIZATION; THROMBIN TIME; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; THROMBOSIS; BIOSYNTHESIS; HEMOPHILIA A;

HEMOPHILIA A; HEMOSTASIS; HUMANS; THROMBIN;

EID: 84957595385     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.10.001     Document Type: Review

References (27)

1. Hoffman M., Monroe D.M. A cell-based model of hemostasis. Thromb Haemost. 2001, 85:958-965.
2. Hartert H.[Not available.] Klin Wochenschr. 1948, 26:577-583.
3. Chitlur M., Rivard G.E., Lillicrap D., et al. Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014, 12:103-106.
4. Young G., Sorensen B., Dargaud Y., et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013, 121:1944-1950.
5. Sorensen B., Johansen P., Christiansen K., et al. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003, 1:551-558.
6. Sorensen B., Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost. 2004, 2:102-110.
7. Beltran-Miranda C.P., Khan A., Jaloma-Cruz A.R., et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005, 11:326-334.
8. Santagostino E., Mancuso M.E., Tripodi A., et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost. 2010, 8:737-743.
9. Chitlur M., Warrier I., Rajpurkar M., et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol. 2008, 142:250-256.
10. Salinas V, Carmona R, Mohammed BM, et al. Is some better than none: are TEG and TGA profiles different in severe FVIII-deficient patients with inhibitors? Haemophilia. 015;21:398-404.
11. Young G., Blain R., Nakagawa P., et al. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006, 12:598-604.
12. Sorensen B., Ingerslev J. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor-clinical outcome and laboratory observations. Thromb Haemost. 2010, 103:1275-1276.
13. Macfarlane R.G., Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol. 1953, 6:3-8.
14. Hemker H.C., Giesen P., AlDieri R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002, 32:249-253.
15. Hemker H.C., Al Dieri R., De Smedt E., et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006, 96:553-561.
16. Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol. 2011, 33:333-342.
17. Hemker H.C., Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost. 1995, 74:134-138.
18. Dargaud Y., Beguin S., Lienhart A., et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005, 93:475-480.
19. Tarandovskiy I.D., Balandina A.N., Kopylov K.G., et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res. 2013, 131:e274-e280.
20. Collins P.W., Bjorkman S., Fischer K., et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010, 8:269-275.
21. Salvagno G.L., Astermark J., Lippi G., et al. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?. Haemophilia 2009, 15:290-296.
22. Al Hawaj M.A., Martin E.J., Venitz J., et al. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 2013, 19:409-414.
23. Barrowcliffe T.W. Monitoring inhibitor patients with the right assays. Semin Hematol. 2008, 45:S25-S30.
24. Dargaud Y., Lienhart A., Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010, 116:5734-5737.
25. Livnat T., Martinowitz U., Zivelin A., et al. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008, 14:782-786.
26. Martinowitz U., Livnat T., Zivelin A., et al. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009, 15:904-910.
27. Tran H.T., et al. Monitoring bypassing agent therapy-a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia 2015, 21:275-283.